​

Olema Pharmaceuticals (OLMA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

OLMA Stock Forecast

Olema Pharmaceuticals (OLMA) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $42.80, with a high of $48.00 and a low of $38.00. This represents a 35.57% increase from the last price of $31.57.

$5 $14 $23 $32 $41 $50 High: $48 Avg: $42.8 Low: $38 Last Closed Price: $31.57

OLMA Stock Rating

Olema Pharmaceuticals stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

OLMA Price Target Upside V Benchmarks

TypeNameUpside
StockOlema Pharmaceuticals35.57%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts799
Avg Price Target$39.43$36.00$36.00
Last Closing Price$31.57$31.57$31.57
Upside/Downside24.90%14.03%14.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 2518---9
Nov, 2527---9
Oct, 2526---8
Sep, 2526---8
Aug, 2535---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 11, 2025Oppenheimer$48.00$31.6651.61%52.04%
Dec 11, 2025Goldman Sachs$38.00$30.6823.86%20.37%
Dec 11, 2025Emily BodnarH.C. Wainwright$45.00$32.2239.66%42.54%
Dec 10, 2025Michael YeeJefferies$43.00$30.6640.25%36.21%
Nov 21, 2025Goldman Sachs$26.00$22.0118.13%-17.64%
Nov 20, 2025Guggenheim$40.00$22.1680.51%26.70%
Nov 18, 2025H.C. Wainwright$36.00$20.1478.75%14.03%
Oct 20, 2025Emily BodnarH.C. Wainwright$28.00$9.36199.15%-11.31%
Oct 08, 2025Guggenheim$20.00$10.4491.57%-36.65%
Oct 24, 2024Richard LawGoldman Sachs$27.00$11.91126.70%-14.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 12, 2025CitigroupBuyBuyhold
Dec 11, 2025OppenheimerOutperformOutperformhold
Dec 11, 2025H.C. WainwrightBuyBuyhold
Dec 10, 2025JefferiesBuyBuyhold
Nov 21, 2025Goldman SachsBuyBuyhold
Nov 20, 2025GuggenheimBuyBuyhold
Oct 20, 2025OppenheimerOutperformOutperformhold
Oct 20, 2025UBSBuyBuyhold
Oct 08, 2025GuggenheimBuyinitialise
Sep 22, 2025OppenheimerBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.14$-2.20----
Avg Forecast$-2.12$-2.30$-2.65$-3.12$-3.20$-1.94
High Forecast$-2.01$-2.20$-2.15$-2.47$-2.55$-1.94
Low Forecast$-2.27$-2.37$-3.29$-3.88$-3.84$-1.94
Surprise %0.94%-4.35%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$4.50M$37.45M$154.40M
High Forecast---$4.50M$37.45M$154.40M
Low Forecast---$4.50M$37.45M$154.40M
Surprise %------

Net Income Forecast

$-180M $-161M $-142M $-123M $-104M $-85M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-96.66M$-129.47M----
Avg Forecast$-96.66M$-103.42M$-123.08M$-143.65M$-144.56M$-87.78M
High Forecast$-90.85M$-99.62M$-97.18M$-111.87M$-115.38M$-87.78M
Low Forecast$-102.94M$-107.21M$-148.98M$-175.44M$-173.75M$-87.78M
Surprise %-25.20%----

OLMA Forecast FAQ

Is Olema Pharmaceuticals stock a buy?

Olema Pharmaceuticals stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Olema Pharmaceuticals is a favorable investment for most analysts.

What is Olema Pharmaceuticals's price target?

Olema Pharmaceuticals's price target, set by 7 Wall Street analysts, averages $42.8 over the next 12 months. The price target range spans from $38 at the low end to $48 at the high end, suggesting a potential 35.57% change from the previous closing price of $31.57.

How does Olema Pharmaceuticals stock forecast compare to its benchmarks?

Olema Pharmaceuticals's stock forecast shows a 35.57% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Olema Pharmaceuticals over the past three months?

  • December 2025: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Olema Pharmaceuticals’s EPS forecast?

Olema Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.65, marking a 20.45% increase from the reported $-2.2 in 2024. Estimates for the following years are $-3.12 in 2026, $-3.2 in 2027, and $-1.94 in 2028.

What is Olema Pharmaceuticals’s revenue forecast?

Olema Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $4.5M, followed by $37.45M for 2027, and $154.4M for 2028.

What is Olema Pharmaceuticals’s net income forecast?

Olema Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-123M, representing a -4.94% decrease from the reported $-129M in 2024. Projections indicate $-144M in 2026, $-145M in 2027, and $-87.779M in 2028.